OnHill, Alginomics, OliX and S-Biomedics attend BIO USA to discuss technology transfers and clinical trials
OnHill, Alginomics, OliX and S-Biomedics participated in BIO USA 6during the month to announce the development of a new drug validation platform, global cooperation on RNA editing, discussions on technology transfers and development, and the pursuit of direct advancement into clinical trials for commercializing TED-A in the United States, respectively.9During the same period, the government declared that it would disperse AI data centers to regional areas.
Get free 에스바이오메딕스 email updates.
Bullstory sends one daily email when new analysis or important company news is available.
OnHill 6in 17Phase 0.5 announced that it had begun developing a validation platform for an Alzheimer’s drug candidate. The company said the platform is intended for use in the early validation stage of new drug candidates.
Alginomics said it discussed global cooperation and partnerships centered on its RNA editing platform at BIO USA. The company said it was seeking ways to expand the platform’s scope of application through cooperation.
OliX said it attended BIO USA to discuss partnerships, including technology transfers and joint development. The company explained that it planned to discuss specific technology transfer conditions and a development roadmap.
S-Biomedics9said it is pursuing the direct progression of TED-A into clinical trials for commercialization in the United States. The company said it is developing its clinical strategy with the potential for commercialization in the U.S. market in mind.
The government announced that it would distribute AI data centers across regions and said the construction industry should be developed as a platform industry rather than merely a construction business. The government said it had presented the principles of distribution and the direction for platformization in the construction sector.
Companies are continuing to seek local partners and discuss clinical trials and technology transfers, and each company said it would provide information on future contracts and clinical plans through relevant disclosures.